Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1166774

	registered interest
	date	28/10/2019
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, what the Government’s policy is on the importation of small amounts of prescribed medical cannabis that have been sourced from abroad.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	6490
	answer	answer is ministerial correction date of answer 05/11/2019 answer text <p><strong><em>It has not proved possible to respond to the hon. Member in the time available before Dissolution.</em></strong></p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 05/11/2019 17:02:31 answering member 4495 label Biography information for Kit Malthouse
	tabling member	4623 label Biography information for Tonia Antoniazzi

1166798

	registered interest
	date	28/10/2019
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, what the Government’s policy is on the importation of legally prescribed medical cannabis for individuals that has been sourced from abroad.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	6493
	answer	answer is ministerial correction date of answer 05/11/2019 answer text <p>There are established lawful routes of supply that are employed for the import of all controlled drugs. As THC is a controlled substance, there is currently an established system in the UK which allows for the lawful importation of THC in CBPM products, through consistent and authorised processes, which deters the need for patients to travel abroad to obtain such products.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 05/11/2019 16:52:51 answering member 4495 label Biography information for Kit Malthouse
	tabling member	4623 label Biography information for Tonia Antoniazzi

1173621

	registered interest
	date	27/01/2020
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, what steps her Department is taking to expedite the processes for granting import licences for cannabis-based products for medicinal use.
	tabling member constituency	Inverclyde
	tabling member printed	Ronnie Cowan
	uin	8362
	answer	answer is ministerial correction date of answer 04/02/2020 answer text <p>All applications are considered individually on their merits and with regards to our obligation under International Conventions and Domestic law. Applications for importation of CBPMs are already expedited, where documentation and regulatory approval is provided, in recognition of the need to ensure continuity of the supply of unlicensed medicines. Applications for import licences are normally decided within a few working days.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 04/02/2020 15:54:19 answering member 4495 label Biography information for Kit Malthouse
	tabling member	4465 label Biography information for Ronnie Cowan

1173622

	registered interest
	date	27/01/2020
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, what meetings (a) she, (b) Special Advisers to ministers in her Department, and (c) officials in her Department have attended with representatives of patient groups on the import of cannabis-based products for medicinal use since 1 January 2018.
	tabling member constituency	Inverclyde
	tabling member printed	Ronnie Cowan
	uin	8363
	answer	answer is ministerial correction date of answer 04/02/2020 answer text <p>Home Office Ministers, Special Advisers and officials have regular meetings as part of the process of policy development and delivery. As was the case with previous administrations, it is not the Government's practice to provide details of all such meetings.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 04/02/2020 15:57:41 answering member 4495 label Biography information for Kit Malthouse
	tabling member	4465 label Biography information for Ronnie Cowan

1196447

	registered interest
	date	18/05/2020
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, with reference to paragraphs 4 and 5 on page 3 of her Department's Factsheet on Cannabis, CBD and other cannabinoids, what assessment she has made of the limit of detection that is the appropriate level of sensitivity to accurately determine through laboratory analysis that there are no controlled cannabinoids present in a CBD product and that the product contains CBD in its pure form.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	48249
	answer	answer is ministerial correction date of answer 02/06/2020 answer text <p>The Department has made no assessment of limits of detection in relation to testing for the presence of controlled cannabinoids in CBD products. The Home Office approach is one of caution, that is, that a CBD product is likely to be controlled under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001 (‘the 2001 Regulations’) if it contains any controlled cannabinoids.</p><p>The term ‘administration’ in the exempt product definition is not defined by the 2001 Regulations. The Human Medicines Regulations 2012 provides the following as part of its definition:</p><p>““administer” means administer to a human being—</p><p> </p><p>(a) orally, by injection, or by introduction into the body in any other way; or</p><p>(b) by external application (whether or not by direct application to the body)”</p><p> </p><p>The interpretation of legislation is ultimately a matter for the courts to decide.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse grouped question UIN 48250 question first answered 02/06/2020 07:41:23 answering member 4495 label Biography information for Kit Malthouse
	tabling member	104 label Biography information for Crispin Blunt

1196456

	registered interest
	date	18/05/2020
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, with reference to limb A of the definition of an exempted product on page five of her Department's Drug Licensing Factsheet - Cannabis, CBD and other cannabinoids, what her Department's definition is of the term administration.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	48250
	answer	answer is ministerial correction date of answer 02/06/2020 answer text <p>The Department has made no assessment of limits of detection in relation to testing for the presence of controlled cannabinoids in CBD products. The Home Office approach is one of caution, that is, that a CBD product is likely to be controlled under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001 (‘the 2001 Regulations’) if it contains any controlled cannabinoids.</p><p>The term ‘administration’ in the exempt product definition is not defined by the 2001 Regulations. The Human Medicines Regulations 2012 provides the following as part of its definition:</p><p>““administer” means administer to a human being—</p><p> </p><p>(a) orally, by injection, or by introduction into the body in any other way; or</p><p>(b) by external application (whether or not by direct application to the body)”</p><p> </p><p>The interpretation of legislation is ultimately a matter for the courts to decide.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse grouped question UIN 48249 question first answered 02/06/2020 07:41:23 answering member 4495 label Biography information for Kit Malthouse
	tabling member	104 label Biography information for Crispin Blunt

1307319

	registered interest
	date	12/04/2021
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, what plans she has to review the levels of THC content allowed in CBD products.
	tabling member constituency	Birmingham, Edgbaston
	tabling member printed	Preet Kaur Gill
	uin	179338
	answer	answer is ministerial correction date of answer 20/04/2021 answer text <p>On 11 January I wrote to the independent Advisory Council on the Misuse of Drugs (ACMD) seeking advice on how we can strengthen and clarify the law on consumer Cannabidiol (CBD) products and ensure that these products contain only a trace percentage of controlled cannabinoids, including THC. The ACMD advice will be published on gov.uk.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 20/04/2021 15:06:14 answering member 4495 label Biography information for Kit Malthouse
	tabling member	4603 label Biography information for Preet Kaur Gill

1343343

	registered interest
	date	02/07/2021
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, what the evidential basis is for cannabis-based products for medical use to be placed alongside fentanyl and diamorphine in Schedule 2 of the Misuse of Drugs Regulations 2001; and if she will make an assessment of the potential merits of placing such products in lower schedule such as Schedule 4.1 alongside Sativex.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	26081
	answer	answer is ministerial correction date of answer 07/07/2021 answer text <p>In February 2019, the then Home Secretary commissioned the ACMD to conduct a longer-term review of Cannabis-Based Products for Medicinal use (CBPM). The ACMD published their report on 27 November 2020 on gov.uk. In it they recommended:</p><p><em>“that the scheduling of CBPMs under Schedule 2 of the MDR remains appropriate and that no further legislative amendments to the MDR regarding CBPMs are required at this point in time.”</em></p><p>Unlike Sativex, most CBPM do not have a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA). As such, in the absence of the reassurance that a CBPM has gone through the safety, quality and efficacy process established by the MHRA, it is right that it is in Schedule 2 of the Misuse of Drugs Regulations 2001. However, should a cannabis-based medicine receive a marketing authorisation from the MHRA, the Government will commission the Advisory Council on the Misuse of Drugs (ACMD) to reconsider the scheduling of the product under the Misuse of Drugs Regulations 2001. This was the case for Sativex following its marketing authorisation.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 07/07/2021 15:37:53 answering member 4495 label Biography information for Kit Malthouse
	tabling member	104 label Biography information for Crispin Blunt

1460066

	registered interest
	date	25/04/2022
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, how many medical cannabis licences have been granted to pharmacies in (a) England, (b) the West Midlands and (c) Birmingham Ladywood in each of the last 12 months.
	tabling member constituency	Birmingham, Ladywood
	tabling member printed	Shabana Mahmood
	uin	158917
	answer	answer is ministerial correction date of answer 28/04/2022 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse grouped question UIN 158918 158919 question first answered 28/04/2022 11:05:43 answering member 4495 label Biography information for Kit Malthouse
	tabling member	3914 label Biography information for Shabana Mahmood

1460067

	registered interest
	date	25/04/2022
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for the Home Department, what estimate her Department has made of the average time taken to award medical cannabis licences to pharmacies following their initial application.
	tabling member constituency	Birmingham, Ladywood
	tabling member printed	Shabana Mahmood
	uin	158918
	answer	answer is ministerial correction date of answer 28/04/2022 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse grouped question UIN 158917 158919 question first answered 28/04/2022 11:05:44 answering member 4495 label Biography information for Kit Malthouse
	tabling member	3914 label Biography information for Shabana Mahmood